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This study examines the hypothesis that transforming
growth factor beta (TGFb) regulates cyclooxygenase-2
(COX-2) and induces prostaglandin E synthase (mPGES-1) in
rat mesangial cells. COX-2 expression was determined by
Northern blot analysis after treatment with either TGFb1 or
the selective COX-2 inhibitor, NS398. mPGES-1 expression
was determined by real-time polymerase chain reaction. The
effect of TGFb1 on COX-2 gene transcription was assessed
using a luciferase reporter assay, and mRNA stability was also
determined. To determine whether TGFb1 activates elements
of the COX-2 promoter, we performed gel shift analyses to
examine activation of activator protein-1 (AP-1) and nuclear
factor jB (NF-jB). Prostaglandin E2 (PGE2) and thromboxane
B2 (TxB2) production was assayed by enzyme immunoassay.
Finally, the pathophysiological relevance of COX-2 inhibition
on the downstream effects of TGFb was assessed by
examining collagen type I mRNA and net collagen
production. COX-2 mRNA and mPGES-1 were induced after
treatment with TGFb1 for 4 h, and this rise was accompanied
by a three-fold increase in PGE2 production that could be
antagonized by selective inhibition of COX-2 with NS398.
TGFb1 increased transcription by approximately 50% and
activated both AP-1 and NF-jB. These effects were
antagonized by co-treatment with NS398. Treatment with
TGFb1 also doubled the half-life of COX-2 mRNA. Neither
collagen type I mRNA nor net collagen production were
altered by co-treatment with NS398. In conclusion, these
results indicate that TGFb stimulates COX-2 and mPGES-1,
with additional effects on transcription and stability of
COX-2 mRNA.
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The role of transforming growth factor beta (TGFb) in the
regulation of extracellular matrix is well recognized1–4 and
many studies demonstrate its role in glomerular disease.
TGFb expression occurs within a few days of the onset of
hyperglycemia,5 and the stimulatory effect of high glucose on
collagen production by cultured mesangial cells can be
reversed by a neutralizing antibody to TGFb6 Prostanoids
have received attention as potential modifiers of matrix
deposition,7,8 and prostaglandin E2 (PGE2) and prostacyclin
(PGI2) are known to decrease extracellular matrix protein
production. However, in the kidney, the relationship between
TGFb and enzymes in the prostanoid synthetic pathway is
unclear.
The inducible isoform of cyclooxygenase, COX-2, is
induced by a variety of growth factors and cytokines to
produce large quantities of prostanoids.9,10 Microsomal
glutathione-dependent prostaglandin E synthase (mPGES-
1) is a downstream enzyme of prostaglandin H synthase-2
and is also inducible and functionally linked with COX-2.11
Few studies have evaluated the role of mPGES-1 in renal
disease, although prostanoid production is increased in a
variety of renal diseases12–14 and is linked to induction of
COX-2.15,16 This is similar to the elevations of TGFb in
glomerular disease.2,4 Recently, we demonstrated that long-
term inhibition of COX-2 with NS398 decreased glomerular
hypertrophy, proteinuria, and collagen type I deposition in
the uninephrectomized spontaneously hypertensive rat
(SHR) and Wistar Kyoto rat (WKY) without affecting
systemic blood pressure.17 Treatment with NS398 also
potentiated the antiproteinuric effect of enalapril. Hence,
our previous in vivo results suggested that COX-2 inhibition
could oppose some of the effects of TGFb. The present
study complements our in vivo study and extends it to
mechanistically examine the interaction between TGFb and
COX-2.
The relationship between TGFb and COX-2 has not been
studied in mesangial cells. However, the non-selective COX
inhibitor, indomethacin, suppresses the antiproliferative
effects of TGFb on fibroblast cell cultures;18 suggesting that
the two pathways are inter-related. Also, treatment of human
lung fibroblasts with TGFb in the presence of interleukin
(IL)-1b increases COX-2 mRNA stability,19 rather than
transcription, despite the fact that the COX-2 gene contains
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a TGFb response element.20 In rat intestinal epithelial cells,
TGFb also increases COX-2 mRNA stability,21 and in
cultured rat mesangial cells, treatment with IL-1b stabilizes
COX-2 mRNA, an effect that is associated with the binding of
a protein to its 30-untranslated region.22 In contrast,
treatment of cultured human lung fibroblasts with IL-1b
increases COX-2 gene transcription.23 Thus, regulation of
COX-2 is cell type specific with both transcriptional and
post-transcriptional mechanisms regulating COX-2 gene
expression.24–26 The human COX-2 gene contains transcrip-
tion factor consensus sequences for nuclear factor kB (NF-
kB), and the nuclear factor of IL-6 within its promoter
region,27 consistent with increased COX-2 expression during
inflammation and in response to treatment with phorbol
esters and cytokines. Additionally, the 30-untranslated region
of human COX-2 contains multiple Shaw–Kamen motifs
(AUUUA sequences) that are present in many immediate-
early genes and target the RNA for rapid degradation. Thus,
the potential exists for COX-2 to be regulated by both
transcriptional and post-transcriptional mechanisms.
Since evidence in other cell types had indicated the
possible regulation of COX-2 by TGFb, we put forward the
hypothesis that TGFb regulates COX-2 expression in the
kidney and examined the effect of TGFb1 on COX-2
expression in cultured glomerular mesangial cells. As TGFb
is known to be an important mediator of fibrosis, we also
examined the effect of COX-2 inhibition with NS398 on
TGFb1-stimulated collagen type I mRNA expression and net
collagen production.
RESULTS
Effect of TGFb on COX-2 mRNA and protein: a time course
In initial experiments to determine the time course of the
effect of TGFb1 on COX-2 mRNA steady-state levels, cells
were treated with 10 ng/ml TGFb1 over 24 h and COX-2
mRNA levels determined by Northern blot analysis. As a
positive control, we also treated cells with 5 ng/ml IL-1b,
which is well known to induce COX-2 mRNA. Figure 1a is a
representative Northern blot showing the effect of IL-1b and
TGFb1 on COX-2 mRNA at the 2 and 4 h time point. Figure
1b shows the entire time course for the effect of IL-1b and
TGFb1 on COX-2 mRNA. As expected, treatment with IL-1b
strongly induced COX-2 mRNA. TGFb1 also induced COX-2
mRNA and produced maximal stimulation between 2 and 4 h
after its addition (Figures 1 and 2).
To ensure that the stimulation of COX-2 mRNA was
attributable to TGFb, a neutralizing antibody to TGFb
(10 mg/ml final concentration; R & D Systems, Minneapolis,
MN, USA) was added for 30 min before the addition of
TGFb1. Cells were then incubated for a further 4 h and total
RNA extracted using standard techniques. Real-time reverse
transcriptase-polymerase chain reaction (RT-PCR) was used
for the detection of COX-2 and b-actin, using SYBR green
technology. Treatment with TGFb1 for 4 h stimulated COX-2
mRNA corrected to b-actin from a control value of 1.00 to
5.2871.55, Po0.05, and this was reduced to 2.3070.20 in
the presence of the neutralizing antibody (P¼ 0.06 compared
to TGFb1 alone).
To determine whether increased COX-2 mRNA resulted in
increased expression of COX-2 protein, we performed
Western blot analysis as shown in Figure 2a. Treatment of
cells with either TGFb1 or IL-1b increased COX-2 protein
(Figure 2b). Expression was consistently detectable 4 h after
the addition of agonist and remained elevated for at least
24 h. At 4 h, TGFb1-stimulated COX-2 protein was 202765
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Figure 1 | Northern blot analysis of COX-2 expression.
(a) A representative Northern blot showing COX-2 mRNA (upper
panel) and 18 s (lower panel) from rat mesangial cells treated with
either Sþ media (control), 5 ng/ml IL-1b, or 10 ng/ml TGFb for 2 or
4 h. (b) A time course showing the effect of either Sþ media
(control), &; IL-1b, ; or TGFb, ’ on COX-2 mRNA over 24 h. Values
shown are mean COX-2 mRNA levels corrected to 18 s from two
separate experiments.
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Figure 2 | Western blot analysis of COX-2 expression. (a) A
representative Western blot for COX-2 protein. (b) The entire time
course for the effects of TGFb ( ) and IL-1b (’) on COX-2 protein
compared to Sþ control (&). ND¼Not detectable. Values are mean
results from three separate experiments. Statistical significance:
*Po0.05 compared to respective time control.
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densitometric units versus 23723 units for the appropriate
time control, Po0.05; and at 24 h, TGFb1-stimulated COX-2
protein was 291789 densitometric units versus 62715 units
for the appropriate time control, Po0.05. Thus, as our data
showed that both COX-2 mRNA and protein were increased
4 h after the addition of TGFb1, we decided to use this time
point in all subsequent experiments.
Effect of TGFb on mPGES-1 mRNA
We also examined whether TGFb1 could affect mPGES-1
mRNA using real-time RT-PCR. mPGES-1 mRNA was
detectable under control (Sþ ) conditions and was increased
after stimulation with TGFb1 for 4 h. The mean crossing
point was 23.8 for Sþ samples and 21.3 for TGFb-treated
cells. mPGES-1 mRNA, corrected to b-actin was set to a value
of 1.00 under control conditions and was increased to
8.8971.96 by TGFb1, Po0.05, n¼ 3 separate experiments.
Effect of NS398 on PGE2 and TxA2 production
To ensure that increased COX-2 mRNA and protein after
treatment with TGFb1 resulted in elevated prostanoid
production, we measured PGE2 and thromboxane A2
(TxA2) (as the stable metabolite thromboxane B2 (TxB2))
production by enzyme immunoassay. This was performed in
the absence and presence of NS398 to ensure that any
changes were owing to induction of COX-2 and not
stimulation of COX-1. Experiments were performed on three
separate occasions using triplicate wells. Treatment with
10 ng/ml TGFb1 increased PGE2 production from
0.2170.033 to 0.4970.1 ng/ml, Po0.05. NS398 antagonized
this stimulatory effect and reduced PGE2 production to
0.2570.04 ng/ml, Po0.05, a value similar to that observed
under basal conditions. This suggested that induction of
COX-2 was responsible for the rise elicited by treatment with
TGFb1. TxA2 production was approximately 20-fold less than
was PGE2. In addition, although TxA2 production was
increased after treatment with TGFb1, the magnitude of this
change was far less than that for PGE2. TGFb1 increased
TxA2 production by approximately 51%, from 9.9770.32
to 15.0771.14 pg/ml, Po0.001, and this was inhibited in
the presence of NS398 (to 11.0270.48 pg/ml, Po0.005,
compared to TGFb1 alone) (Figure 3).
Effect of NS398 on COX-2 expression
As previous studies had reported that COX-2 inhibitors
affect COX-2 expression, we proceeded to examine the effect
of NS398 on basal and TGFb1-stimulated COX-2 expres-
sion. Figure 4a is a representative Northern blot showing the
ability of NS398 to antagonize the effect of TGFb1 on COX-
2 mRNA expression. The addition of 10 ng/ml TGFb1 for
4 h increased COX-2 mRNA levels (corrected to 18 s) by
3.2770.51-fold, Po0.001, n¼ 7, and this increase was
reduced in the presence of 10 mM NS398 to 1.8470.32-fold,
Po0.05. Treatment with NS398 alone had no effect
on COX-2 mRNA levels and was 0.8970.16 of control
(Figure 4b).
Effect of TGFb on COX-2 promoter activity and mRNA
stability
Figure 5 shows that treatment with TGFb1 for 4 h increased
COX-2 promoter activity to 143.6715.6% of control
(Po0.05, n¼ 5). NS398 did not alter baseline COX-2
promoter activity (96.379.7% of control) but antagonized
the effect of TGFb1, reducing it to 63.675.3% of control
(Po0.005 versus TGFb1 alone).
To determine whether TGFb1 affects COX-2 mRNA
stability, cells were treated with either IL-1b alone or
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Figure 3 | Effect of TGFb and NS398 on PGE2 and TxA2
production. Bar graph showing the effect of treatment with either
Sþ media alone (control) or 10 ng/ml TGFb1 for 4 h on PGE2 (a) and
TxA2 production (b) in the presence and absence of 10 mM NS398.
Note the different units for the axes. Values are means7s.e.m. from
three separate experiments performed in triplicate. Statistical
significance: *Po0.05 and ***Po0.005 compared to Sþ control.
þPo0.05 and þ þ þPo0.005 compared to values in the absence of
NS398.
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Figure 4 | Effect of TGFb and NS398 on COX-2 mRNA. (a) A
representative Northern blot showing the effect of TGFb1, NS398, or
a combination of both on COX-2 mRNA. (b) A bar graph showing the
effect of treatment with 10 ng/ml TGFb1, 10mM NS398, or both for 4 h
on COX-2 mRNA, corrected to 18 s. Values are means7s.e.m. from
seven separate experiments. Statistical significance: ***Po0.005
compared to Sþ control, and þPo0.05 compared to TGFb1 alone.
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IL-1bþTGFb1 for 3 h and the transcriptional inhibitor,
5,6-dichloro-1-b-D-ribofuranosylbenzimidazole, was added
at time zero. As COX-2 mRNA under control conditions
(Sþ media) is of low abundance, we used IL-1b to stimu-
late COX-2 mRNA, so that decay could be clearly observed.
In two separate experiments, the mean half-life of IL-1b-
stimulated COX-2 mRNA was approximately 14 min and
the addition of TGFb1 lengthened this to approximately
32 min.
Effect of TGFb1 and NS398 on AP-1 and NF-jB binding
Treatment with 10 ng/ml TGFb1 maximally stimulated
activator protein-1 (AP-1) binding 1 h after its addition
(Figure 6). Thus, this time was chosen in all subsequent
experiments. As shown in Figure 6, we observed only one
band that co-migrated with the positive control HeLa cell
nuclei that were provided with the kit and did not observe
any bands when the incubation mixture lacked nuclei
(negative control). Figure 7 is a representative gel showing
the effect of NS398 on TGFb1-induced AP-1 binding. In
three separate experiments, we observed that co-treatment
with NS398 could antagonize the binding elicited by TGFb1,
as shown in the figure. As NF-kB is also known to regulate
COX-2, we examined the effect of TGFb1 and NS398 on NF-
kB binding. Similar to AP-1 binding, treatment with TGFb1
for 1 h increased NF-kB binding and this effect was abolished
in the presence of NS398 (Figure 8a). Figure 8b shows that
NF-kB binding in response to TGFb could be displaced with
a 100-fold excess of ‘cold’ oligonucleotide probe.
Effect of NS398 on collagen I mRNA and net collagen
production
Treatment with TGFb1 for 72 h resulted in a two-fold
increase in collagen type I mRNA that was unaffected after
co-treatment with NS398. Collagen type I mRNA, corrected
to 18S, was 2.1070.06 units in cells treated with TGFb1 for
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Figure 5 | Bar graph showing COX-2 promoter activity (relative
luciferase activity) after treatment with either 10 ng/ml TGFb1,
10 lm NS398, or a combination of the two for 4 h. Cells were
transiently transfected with either the full-length mouse COX-2
promoter in pGL2 enhancer vector or a promoterless vector for 20 h
before treatment. Values are normalized for protein and Sþ control
was set to 100%. Statistical significance: *Po0.05 compared to
Sþ control, and þ þ þPo0.005 compared to TGFb1 alone. n¼ 5
separate experiments.
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Figure 6 | Representative gel showing a time course for
TGFb1-induced AP-1 binding.  and þ represent without and with
10 ng/ml TGFb1 for the indicated times. C is a negative control lane in
which no nuclei were added to the incubation mixture. HeLa cell
nuclei are a positive control and are provided with the kit.
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Figure 7 | Gel-shift assay showing AP-1 binding after treatment
with either media alone (Sþ ), 10 ng/ml TGFb1, 10 lM NS398, or a
combination of both for 1 h. Gels are representative of three
separate experiments.
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Figure 8 | NF-jB binding in response to TGFb. (a) Gel-shift assay
showing NF-kB binding after treatment with either media alone
(Sþ ), 10 ng/ml TGFb1, 10mM NS398, or a combination of both for 1 h.
Gels are representative of three separate experiments. (b) NF-kB
binding in response to TGFb can be displaced by a 100-fold excess of
cold oligonucleotide.
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72 h (Po0.005 compared to control) and was 2.0870.11
units in cells treated with TGFb1 and NS398.
Treatment with 10 ng/ml TGFb1 for 72 h elicited a small
but significant increase in hydroxyproline content, from
29.7670.97 to 34.0671.59 mg hydroxyproline, Po0.05,
n¼ 5. This increase was unaffected after co-treatment with
NS398 (34.0671.59 mg for TGFb1 versus 32.1270.72 for
TGFbþNS398, P¼ 0.15).
DISCUSSION
This study clearly demonstrates that COX-2 expression in
glomerular mesangial cells is regulated by TGFb. To our
knowledge, this is also the first study to show that TGFb
increases mPGES-1 in the kidney. The induction of COX-2
and mPGES-1 by TGFb1 is robust and provides for an
increase in PGE2 production that can be inhibited by the
selective COX-2 inhibitor, NS398. Additionally, this increase
appears to be mediated by changes in both COX-2 mRNA
stability and increases in COX-2 transcription.
Treatment with NS398 reduced TGFb-stimulated COX-2
mRNA and also reduced COX-2 promoter activity under the
same conditions. Although one would not expect an enzyme
inhibitor to affect mRNA levels, other studies have reported
similar findings regarding COX-2 inhibitors.28,29 Inoue
et al.30 showed that PGE2, acting through the PGE2 receptor
subtypes EP2 and EP4 via cAMP, could stimulate COX-2
expression. Thus, one might anticipate that the reduction
of PGE2 observed after NS398 would decrease COX-2
expression.
The fact that COX-2 reporter activity was increased by
TGFb1 was not surprising given that the COX-2 promoter
contains a TGFb response element.20 Although we used the
mouse COX-2 promoter in rat mesangial cells, there is a high
degree of homology between the two species and common
transcriptional elements, making it likely that similar results
would have been found if we had access to and used the rat
COX-2 promoter.31 In our studies, treatment with TGFb1
was able to increase binding to both AP-1 and NF-kB
consensus oligonucleotides, suggesting that TGFb1 may
activate these elements to regulate the COX-2 promoter.
Likewise, the ability of NS398 to inhibit this activation may
explain how this COX-2 inhibitor inhibits TGFb-induced
COX-2 promoter activity. Whether these effects of NS398 are
independent of prostanoid production cannot be discerned
by this present study. Recently, Gaedeke et al.32 showed that
the AP-1 inhibitor, Curcumin, could oppose TGFb-stimu-
lated collagen I mRNA, fibronectin, and plasminogen
activator inhibitor-1 in renal fibroblasts, and both Wong
et al.33 and Kim et al.34 demonstrated that a different COX-2
inhibitor (SC-236) could suppress stimulated AP-1 and NF-
kB activation in gastric cancer cells and a human mast cell
line, respectively. In contrast to Gaedeke et al., our study did
not observe any effect of NS398 on collagen type I mRNA
despite decreased activation of AP-1. Whether this relates to
the different cell types used or duration of treatment remains
unknown.
The relatively small increase in transcription appears
unlikely to account for the large increase in steady-state levels
of COX-2 mRNA after treatment with TGFb1. Thus, as
shown in the present study, TGFb increases COX-2 mRNA by
both transcriptional and post-transcriptional mechanisms in
mesangial cells. Sheng et al.21 reported that TGFb enhances
Ha-ras-induced expression of COX-2 in intestinal epithelial
cells by the stabilization of its mRNA. Likewise, Dean et al.35
demonstrated that p38, a second messenger of TGFb
signaling, increased COX-2 mRNA stability and transcription
in lipopolysaccharide-treated human monocytes.
In experiments to determine whether the rise in COX-2
expression was associated with increased prostanoid produc-
tion, we measured both PGE2 production and TxA2 in the
culture media by enzyme immunoassay. PGE2 production
was increased by the addition of TGFb1 for 4 h and this rise
was inhibited by NS398. TxA2 production was approximately
20-fold less in cultured rat mesangial cells grown in serum
than was PGE2. In addition, although TxA2 production was
increased after treatment with TGFb, the magnitude of this
change was far less than that for PGE2. These results are in
agreement with those of other investigators who report that
induction of COX-2 is more intimately linked with PGE2
production in preference to that of other prostanoids.36,37
Consistent with this observation, our results also show that
treatment with TGFb1 was able to induce/stimulate mPGES-
1 mRNA. Petry et al.38 reported an inability to detect mPGES
in mesangial cells using immunohistochemistry. Similarly,
Campean et al.39 reported a lack of mPGES in mesangial cells,
although rat glomeruli were positive by RT-PCR. Our
experiments using the sensitive technique of real-time RT-
PCR are in contrast to the above results in that we clearly
detect mPGES-1 in cultured mesangial cells grown in serum
and demonstrate a robust increase after treatment with
TGFb. Thus, induction of both COX-2 and mPGES-1 by
TGFb explains how PGE2 production is selectively increased
in our study.
The pathophysiological impact of the interaction between
TGFb and COX-2 was assessed by studying collagen
expression and production. In contrast to our previously
published in vivo data, NS398 had no effect on TGFb1-
stimulated expression of collagen in cultured mesangial cells.
It is possible that these discrepancies are owing to duration of
treatment, concentration of NS398 achieved in vivo, or to the
involvement of different cell types. However, the stimulation
of both COX-2 and mPGES-1 expression by TGFb1 is likely
to have pathophysiological significance. One might anticipate
that sustained elevations in TGFb could result in a vicious
circle whereby the inflammatory response to injury is
perpetuated. Indeed, COX-2 products are known to be
chemotactic, vasodilatory, and modulators of cell growth.40,41
A number of in vivo studies,42–44 including one from our
laboratory,17 demonstrate that inhibition of COX-2 is
beneficial in various forms of renal disease with regard to
both matrix deposition and other indices of renal function
such as proteinuria. Thus, the stimulation of COX-2 and
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mPGES-1 by TGFb noted in this present study has relevance
to diverse glomerular diseases characterized by inflammation
and/or sclerosis.
MATERIALS AND METHODS
Materials
Human recombinant IL-1b was obtained from Promega (Madison,
WI, USA) and human recombinant TGFb1 was from R & D systems
(Minneapolis, MN, USA).
Mesangial cell culture
Mesangial cells derived from Sprague–Dawley rats were grown in
RPMI 1640þ 16.7% fetal calf serum and were used between
passages 10 and 20. These cells have been characterized previously.45
Northern blotting for COX-2, collagen a2I, and a-SMA mRNA
Total RNA was used for Northern blot analysis using standard
techniques. cDNAs for rat COX-2 and rat collagen a2I were
provided by Dr Raymond Harris at Vanderbilt University, Nashville,
TN, USA and Dr Svend Freytag at Henry Ford Hospital, Detroit, MI,
USA, respectively. After probing for the respective mRNA, blots were
stripped and re-probed for 18 s as a loading control.
To ensure that the stimulation of COX-2 mRNA was attributable
to TGFb1, a neutralizing antibody to TGFb1, 10 mg/ml final
concentration (R & D Systems, Minneapolis, MN, USA), was added
for 30 min before the addition of TGFb1. Cells were incubated for a
further 4 h and total RNA was extracted using standard techniques.
Real-time RT-PCR was used for the detection of COX-2 and b actin,
using SYBR green technology.
Real-time RT-PCR for COX-2 and mPGES-1
Real-time RT-PCR for COX-2 was performed as follows: 1 mg RNA
sample was treated with DNAse I and subsequently reverse
transcribed using specific antisense primers against COX-2 and a
reference gene (b-actin). Standards for quantification were prepared
by amplifying serial dilutions of known concentrations of templates
for each gene. A measure of 2 ml of either standard or sample was
amplified using a LightCycler PCR instrument (Roche, Indianapolis,
IN, USA). Amplification of COX-2 and b-actin cDNAs were
monitored in separate reactions in real-time using SYBR green dye
(Qiagen, Valencia, CA, USA). The following primer sequences were
used: COX-2 sense, 50-ggcaatagaaataaatataaaacaataatgac-30; COX-2
antisense, 50-acgtgtgtaggtgagt-30; b-actin sense, 50-acccacactgtgcc
catcta-30; b-actin antisense, 50-gccacaggattccataccca-30.
Reactions were set up in a final volume of 20ml, which contained
2 ml of standard or diluted sample, 4 mM MgCl2, 1mM each of both
the primers and 10 ml of 2 SYBR green PCR mix. The following
cycling parameters were used for the amplification: denaturation at
951C for 15 s, annealing at 571C for 45 s, and extension at 721C for
90 s, for a total of 30 cycles.
Crossing points of sample genes were compared against crossing
points of known standards. Values for COX-2 were normalized to
b-actin amplified from the same sample. At the end of PCR cycling,
melting curve analyses were performed and representative PCR
products were run on polyacrylamide gels and visualized by
ethidium bromide staining. Additionally, the PCR product was
verified to be COX-2 by sequencing.
In more recent experiments to detect mPGES-1, we used the
Quantitect Probe PCR kit (Qiagen, Valencia, CA, USA) for real-time
analysis with FRET probes and primers designed by TIB MolBiol
(Adelphia, NJ, USA). mPGES-1 mRNA was normalized to b-actin
mRNA. The sequences of the primers/probes are as follows: mPGES-
1 sense, 50-cgcggtggctgtcatca-30; mPGES-1 antisense, 50-agggttgggtc
ccaggaat-30; mPGES-1 FL probe, 50-gagtgacccagatgtggagcgct-30;
mPGES-1 LC probe, 50-LC-red 640-cctcagagcccaccgcaacgac-p-30;
b-actin sense, 50-acccacactgtgcccatcta-30; b-actin antisense, 50-gccaca
ggattccataccca-30; b-actin FL probe, 50-gccacgctcggtcaggatcttcat-x-30;
and b-actin LC probe, 50-LC-red 705-aggtagtctgtcaggtcccggcca-p-30.
For analysis of mPGES-1 (203 bp) and b-actin (342 bp) cDNA, PCR
conditions were 0 s at 951C for denaturation, 40 s at 581C for
annealing, and 40 s at 721C for extension for 40 cycles.
Western blotting for COX-2
To detect COX-2 protein, cells were washed with phosphate-
buffered saline and scraped in lysis buffer (50 mM HEPES, pH 7.4,
150 mM NaCl, 1% (v/v) ethylenediaminetetraacetic acid, 10% (v/v)
Triton X-100, 10% (w/v) glycerol, 1 mM phenylmethylsulfonyl
fluoride, 10mg/ml aprotinin, 10 mg/ml leupeptin, 10 mM sodium
orthovanadate, 25 mM NaF). Lysates were incubated for 30 min on
ice and the supernatants collected after centrifugation at 15 000 g for
15 min. Protein (15 mg) was run on an 11% gel under reducing
conditions and was electroblotted onto a polyvinylidine fluoride
membrane. COX-2 protein was detected using a goat anti-rat
polyclonal antibody to COX-2 at a dilution of 1:2000 (Santa Cruz
Biotechnology Inc., Santa Cruz, CA, USA) followed by incubation
with a horseradish peroxidase-conjugated secondary antibody at a
dilution of 1:20 000. Detection was achieved using an enhanced
chemiluminescence kit (ECL; Amersham Biosciences Corp.,
Piscataway, NJ, USA).
Determination of COX-2 mRNA stability
To determine COX-2 mRNA stability, cells were stimulated for 3 h
with either 5 ng/ml IL-1b alone or a combination of IL-1b plus
10 ng/ml TGFb1 before the addition of the transcriptional inhibitor,
5,6-dichloro-1-b-D-ribofuranosylbenzimidazole (60 mM), at time
zero. 5,6-Dichloro-1-b-D-ribofuranosylbenzimidazole preferentially
inhibits RNA polymerase II and thus affects mRNA synthesis more
than ribosomal RNA synthesis.46 Total RNA was extracted from cells
at 30 min, 1, 2, and 4 h after the addition of 5,6-dichloro-1-b-D-
ribofuranosylbenzimidazole and analyzed for COX-2 mRNA by
Northern blot. COX-2 mRNA, corrected to 18 s, was set to 100% at
time zero for each experimental condition and the decay curve over
the 4 h time period was drawn.
Determination of COX-2 transcriptional activity
COX-2 transcriptional activity was determined using luciferase
reporter activity. The full-length mouse COX-2 promoter in a pGL2
enhancer vector (Promega, Madison, WI, USA) was provided to us
by Dr Raymond Harris at Vanderbilt University. Cells were
transiently transfected for 20 h using 1 mg reporter DNA in serum-
free media using the Fugene 6 transfection reagent (Roche
Diagnostics Corporation, Indianapolis, IN, USA). A further 1 ml
of media were then added and cells were treated for an additional 4 h
with either vehicle alone, 10 ng/ml TGFb1, 10 mM NS398, or a
combination of both. At this concentration, NS398 is a specific
inhibitor of COX-2 and does not affect COX-1 activity.47 At the end
of the experimental period, cells were scraped in reporter lysis buffer
and luciferase activity was determined according to the manufac-
turer’s instructions. In these experiments, the results are corrected to
protein concentration and are reported as relative luciferase activity
per mg protein.
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Preparation of nuclei and DNA-binding studies
To prepare nuclei, cells were washed and scraped in ice-cold Tris-
buffered saline. They were then centrifuged at 1500 g for 5 min and
the pellet resuspended in 400 ml of buffer containing 10 mM HEPES,
pH 7.9, 10 mM KCl, 0.1 mM ethylenediaminetetraacetic acid, 0.1 mM
ethyleneglycol tetraacetate, and 1 mM dithiothreitol. Cells were
allowed to swell on ice for 15 min before the addition of 25 ml
10% NP-40, and after vigorous vortexing, they were centrifuged at
1500 g for 30 s. The nuclear pellet was resuspended in 50 ml of high
salt buffer (20 mM HEPES, pH 7.9, 0.4 M NaCl, 1 mM ethylenedia-
minetetraacetic acid, 1 mM ethyleneglycol tetraacetate, 1 mM dithio-
threitol, 1 mM phenylmethylsulfonyl fluoride) and the tube was
agitated for 15 min at 41C on a shaking platform. The nuclear debris
was discarded after centrifugation at 12 000 g for 5 min and aliquots
of the supernatant were stored at 801C until use.
To determine whether TGFb1 binds to consensus elements
present in the COX-2 promoter, we performed an electrophoretic gel
mobility shift assay with the use of the gel shift assay system
(Promega, Madison, WI, USA) according to the to the manufac-
turer’s instructions. Consensus oligonucleotides for AP-1 and
NF-kB binding sites were radiolabeled using T4 polynucleotide
kinase and [g-32P]ATP and purified by centrifugation through G25
Sephadex spin columns. Nuclear protein (1.5 mg) was incubated
with 50 000–100 000 c.p.m. of labeled oligonucleotide for 20 min at
room temperature in binding buffer (20% glycerol, 5 mM MgCl2,
2.5 mM ethylenediaminetetraacetic acid, 2.5 mM dithiothreitol,
250 mM NaCl, 50 mM Tris–HCl, pH 7.5, 0.25 mg/ml poly(dIdC)).
The samples were run on an 8% polyacrylamide gel in 0.5Tris
borate EDTA at 41C, and after electrophoresis, the gel was dried and
exposed to X-ray film.
Initially, we examined the effect of TGFb1 on AP-1 binding over
24 h and subsequently used 1 h of treatment, a time at which
maximum stimulation was observed. Cells were serum starved for
24 h, then treated with 10 ng/ml TGFb1. In experiments designed to
investigate the ability of NS398 to interfere with this binding, cells
were pre-treated with 10mM NS398 for 1 h before the addition of
TGFb1.
Determination of PGE2 and TxB2 production
PGE2 and TxB2 production into the culture media was measured
after treatment of cells with either media alone, 10 ng/ml TGFb1,
10 mM NS398, or both TGFb1 and NS398. Cells were treated with the
appropriate agents for 4 h in Sþ media, after which they were
washed and changed to serum-free conditions. After an additional
hour, the media were collected and were stored at 801C before a
determination of PGE2 or TxB2 (the stable metabolite of TxA2 by
enzyme immunoassay; Cayman Chemical, Ann Arbor, MI, USA).
Determination of net collagen production using the
hydroxyproline assay
Cells at 50% confluence were washed and treated with either media
alone (Sþ ), 10 ng/ml TGFb1, 10mM NS398, or a combination of
both for 72 h. Media were then removed and two volumes of 100%
ethanol added. After precipitation for 24 h at 201C, samples were
centrifuged at 30 000 g for 30 min (41) and the pellet air-dried before
resuspension in 600 ml of 6 M HCl. The sample was then hydrolyzed
for 16 h at 1101C, dried under nitrogen gas, and resuspended in
water. Duplicate aliquots of sample were assayed for hydroxyproline
content using the spectrophotometric determination of Stegeman
and Stalder48 and a standard curve that ranged from 0 to 7.5 mg
hydroxyproline.
Statistical analysis
Differences between treatment groups were analyzed using an
unpaired t-test. A P-value of less than 0.05 was considered
significant.
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